Future Oncology · 2013 · 23 citations · 56 references
MedicineGeriatric MedicineOncologyGeriatric AssessmentGeriatricsGerontologyComprehensive Geriatric AssessmentFrailty AssessmentFrailty ScreeningGeriatric Health AssessmentGeriatric OncologyPhysical FrailtyAge-specific Risk AssessmentBiological Age AssessmentFrailty Risk AssessmentFrailty Screening ToolsGeriatric Assessment ToolsGeriatric Comprehensive AssessmentRisk-benefit Ratio AssessmentRoutine Frailty Screening
Management of older breast cancer patients is challenging due to a lack of good quality evidence regarding the role of adjuvant chemotherapy. Older women can benefit as much from adjuvant chemotherapy as younger women, although they have an increased risk of toxicities. Decisions regarding adjuvant chemotherapy should be made based on tumor biology and biological age, rather than chronological age. Geriatrician assessment can detect subtle functional deficits that may impact on the ability of the patient to tolerate chemotherapy; however, implementation of comprehensive geriatric assessment in the oncology setting is challenging. Instead, numerous frailty screening tools are in development. Future advances should incorporate more accurate and efficient means for determining the biological age of elderly breast cancer patients, which will better define the risk:benefit ratio of adjuvant chemotherapy.
56
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Soonmyung Paik, Steven Shak, Gong Tang et al. · New England Journal of Medicine · 2004 · 6.4K citations · Full text
Medicine, Oncology, Breast Oncology +12
Kathy S. Albain, William E. Barlow, Steven Shak et al. · The Lancet Oncology · 2009 · 1.4K citations · Full text
Medicine, Oncology, Breast Oncology +12